Adagene (ADAG) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Adagene Inc. showcased promising clinical data at the SITC meeting, highlighting the safety and efficacy of its novel anti-CTLA-4 therapy, ADG126, in combination with pembrolizumab for treating metastatic colorectal cancer. The therapy demonstrated enhanced therapeutic potential and safety profiles, offering hope for improved cancer treatment strategies. These findings underscore ADG126’s potential as a leading therapy in the immunotherapy landscape.
For further insights into ADAG stock, check out TipRanks’ Stock Analysis page.
